Latest Poll Shows Trump's Approval Rating Declining, Analysts Say Markets Should Focus on Midterm Election Risks
Svmuu According to the latest poll from NBC, Trump's approval rating among registered voters has dropped 3 percentage points from 47% in March 2025 to 44%, with his disapproval rate climbing to 54%. The Decision Desk HQ polling average shows a similar result: 43.1% approval, 54.4% disapproval. Investinglive analyst Adam Button stated that for the markets, the key lies in the dynamics of the midterm elections. Trump himself has also pointed out this risk, noting the historical pattern that the party controlling the White House typically suffers setbacks in midterm elections. If Republicans lose seats in Congress, it would reshape the legislative landscape regarding tax policy, tariffs, deregulation, and other areas, and current stock valuations have to some extent already priced in expectations for these policies. The next big question is whether Trump will begin to face internal pressure to end the war quickly. Republicans have certainly acknowledged they are likely to lose the House, and with the Middle East war disillusioning part of their base, control of the Senate is also becoming increasingly uncertain.
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
3
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
4
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
5
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
6
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
7
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
8
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
9
NVIDIA and AMD: The Two Giants of AI Computing Power in 2026—An Analysis of Market Dynamics, Financial Performance, and Opportunities for Transition into Cryptocurrency Mining
-
10
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
Markets Today
Recommended Reading









